Stifel Nicolaus cut shares of AnaptysBio (NASDAQ:ANAB) from a buy rating to a hold rating in a research note published on Friday morning, Briefing.com Automated Import reports. The firm currently has $74.00 price target on the biotechnology company’s stock, down from their previous price target of $124.00.
Several other analysts also recently issued reports on the stock. Wedbush reissued an outperform rating on shares of AnaptysBio in a research note on Friday, March 1st. Guggenheim started coverage on shares of AnaptysBio in a research note on Friday, February 22nd. They set a buy rating and a $135.00 target price on the stock. Cantor Fitzgerald reissued a buy rating and set a $140.00 target price on shares of AnaptysBio in a research note on Wednesday, February 27th. Zacks Investment Research raised shares of AnaptysBio from a sell rating to a buy rating and set a $77.00 target price on the stock in a research note on Wednesday, March 6th. Finally, Credit Suisse Group downgraded shares of AnaptysBio from an outperform rating to a neutral rating and cut their target price for the company from $137.00 to $79.00 in a research note on Friday. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. AnaptysBio has an average rating of Buy and a consensus target price of $111.25.
Shares of NASDAQ:ANAB opened at $53.81 on Friday. AnaptysBio has a one year low of $53.45 and a one year high of $110.00. The firm’s fifty day moving average is $71.29. The firm has a market cap of $1.60 billion, a P/E ratio of -21.52 and a beta of 1.97.
AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.01. On average, analysts anticipate that AnaptysBio will post -3.76 earnings per share for the current year.
In other news, insider Marco Londei sold 10,060 shares of the company’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $73.06, for a total value of $734,983.60. Following the transaction, the insider now directly owns 32,437 shares of the company’s stock, valued at $2,369,847.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Hamza Suria sold 22,428 shares of the company’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $73.76, for a total transaction of $1,654,289.28. Following the completion of the transaction, the chief executive officer now directly owns 31,524 shares in the company, valued at $2,325,210.24. The disclosure for this sale can be found here. Corporate insiders own 14.00% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of ANAB. Millennium Management LLC increased its stake in shares of AnaptysBio by 11,829.2% in the fourth quarter. Millennium Management LLC now owns 258,624 shares of the biotechnology company’s stock worth $16,498,000 after acquiring an additional 256,456 shares during the last quarter. BlackRock Inc. boosted its holdings in AnaptysBio by 11.7% in the fourth quarter. BlackRock Inc. now owns 1,816,825 shares of the biotechnology company’s stock worth $115,894,000 after purchasing an additional 189,685 shares in the last quarter. Redmile Group LLC boosted its holdings in AnaptysBio by 36.5% in the first quarter. Redmile Group LLC now owns 496,918 shares of the biotechnology company’s stock worth $36,300,000 after purchasing an additional 132,868 shares in the last quarter. Advisor Group Inc. bought a new stake in AnaptysBio in the fourth quarter worth $7,827,000. Finally, Norges Bank bought a new stake in AnaptysBio in the fourth quarter worth $7,413,000.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Read More: Why are percentage decliners important?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.